Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of RLS-0071 Treatment for Hospitalized Patients with Steroid-Resistant Acute Graft-versus-Host Disease (aGvHD)

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on evaluating a new treatment for patients with steroid-refractory acute graft-versus-host disease, a condition that can occur after stem cell transplantation when the donated cells attack the recipient's body. The study tests a medication called RLS-0071, which is given through intravenous infusion, in combination with standard treatment.

The study aims to determine if RLS-0071 is safe and effective for treating this condition. Patients will receive different doses of RLS-0071 over a period of up to 14 days. Some patients will also receive another medication called ruxolitinib as part of their treatment. The treatment will be given to patients while they are in the hospital.

During the study, doctors will monitor how well patients respond to the treatment by checking their symptoms, particularly those affecting the skin, liver, and digestive system. They will also track changes in the patients' condition for up to 180 days after starting treatment. The study will measure various aspects of patient recovery, including pain levels, ability to eat, and overall well-being.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial eligibility verification

    Your eligibility will be confirmed based on specific criteria, including being over 12 years old and having completed stem cell transplantation with adequate neutrophil recovery.

    Your weight should be between 40 kg and 140 kg, and you must have specific blood test results within required ranges.

    You must be hospitalized with acute graft versus host disease (aGvHD) and have a minimum performance status score.

  2. Step 2

    Treatment initiation

    You will receive RLS-0071 through an infusion in the hospital.

    The treatment will be given together with or within 48 hours of starting another medication called ruxolitinib (unless this medication is not suitable for you).

    The initial treatment period with RLS-0071 lasts 7 days.

  3. Step 3

    Monitoring period

    Your response to treatment will be evaluated at specific time points: days 7, 14, 28, 56, and 180.

    Regular blood tests will be performed to monitor your condition.

    Your symptoms will be assessed, particularly focusing on skin condition, liver function, and digestive system symptoms.

  4. Step 4

    Follow-up assessments

    Your overall health status will be monitored through various tests and examinations.

    The medical team will track any changes in your condition and symptoms.

    Blood samples will be collected to measure specific markers related to your condition.

    Your quality of life and specific symptoms will be evaluated using standardized questionnaires.

  5. Step 5

    Study completion

    The study continues until day 180 after treatment initiation.

    Long-term monitoring will include survival assessment and evaluation of disease status.

    Final assessments will be conducted to evaluate the overall effectiveness of the treatment.

Who can join the trial?

16 criteria

  • Must be at least 12 years old
  • Must have recovered from stem-cell transplantation with blood neutrophil count (a type of white blood cell) above 500/mL for at least 3 consecutive measurements
  • Must meet the following blood test requirements: - Neutrophil count above 1000/mL without growth factor support - Platelet count above 50,000/mL without transfusions - Liver function tests (AST and ALT) less than 5 times normal limits - Blood bilirubin less than 6mg/dL - Normal blood clotting function
  • Body weight must be between 40 kg and 140 kg
  • Must provide written informed consent (and assent for minors)
  • Must be able to communicate effectively with study staff and follow study requirements
  • Women who can become pregnant must use effective birth control during treatment and for 6 months after
  • Men with partners who can become pregnant must use effective birth control during treatment and for 3 months after
  • Must have received first-time stem cell transplant from a donor for blood cancer treatment
  • Must have steroid-resistant acute graft versus host disease (condition where transplanted cells attack the body) that hasn't improved with standard steroid treatment
  • Must have Grade II-IV acute graft versus host disease affecting skin, liver, or digestive system
  • Must be hospitalized with a Karnofsky Performance Status (measure of patient's ability to perform ordinary tasks) of at least 50
  • Expected hospital stay must be at least 1 week
  • Must be starting or recently started treatment with a medication called ruxolitinib, unless contraindicated
  • Must be able to start study medication (RLS-0071) within 48 hours of starting ruxolitinib
  • Must not plan to change other medications for graft versus host disease during the first 7 days of treatment

Who cannot join the trial?

15 criteria

  • Age below 12 years or over 75 years
  • Known allergic reactions to medications similar to RLS-0071
  • Active uncontrolled infections
  • Severe liver problems (defined as liver enzymes more than 3 times above normal levels)
  • Severe kidney problems (requiring dialysis)
  • Pregnancy or breastfeeding
  • Participation in other clinical trials within the last 30 days
  • Active cancer other than the condition that required stem cell transplant
  • Uncontrolled heart conditions
  • History of severe allergic reactions or anaphylaxis (a serious, life-threatening allergic reaction)
  • Mental conditions that could affect ability to provide informed consent
  • Use of medications that could interact with the study drug
  • Severe breathing problems requiring oxygen support
  • History of organ transplant other than stem cell transplant
  • HIV, hepatitis B, or hepatitis C infection
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

RLS-0071 is an investigational medication being studied for the treatment of acute graft versus host disease (aGvHD), a condition that can occur after bone marrow transplantation. The medication is being tested in patients who have not responded well to steroid treatment. This therapy aims to help manage the complications when the transplanted cells attack the recipient's body tissues. The study is looking at how safe the medication is and how well it works in treating this serious condition.

What is already known about the treatment

RLS-0071 - An investigational drug currently being studied in clinical trials for the treatment of acute graft versus host disease (aGvHD), particularly in steroid-refractory cases. The medication is undergoing Phase 2 clinical trials to evaluate its safety, tolerability, and effectiveness in hospitalized patients. While the exact mechanism of action is still being studied through pharmacodynamic assessments, the drug is being tested to determine its optimal dosing and potential therapeutic benefits in managing transplant complications. The trial aims to measure the overall response rate at 28 days of treatment and establish the drug's safety profile in patients who haven't responded adequately to steroid therapy.

Investigated diseases

Acute Graft versus Host Disease (aGvHD) - A condition that occurs after bone marrow or stem cell transplantation when the donated immune cells attack the recipient's body tissues. The disease typically develops within the first 100 days after transplantation and primarily affects the skin, liver, and gastrointestinal tract. The condition begins when the transplanted cells recognize the recipient's tissues as foreign and launch an immune response against them. The severity can range from mild to severe, with symptoms developing rapidly over days or weeks. Common manifestations include skin rashes, liver dysfunction, and digestive system problems including diarrhea and abdominal pain.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-510582-42-02Protocol codeRLS-0071-203Estimated enrolment60 patientsSponsorRealta Life Sciences Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.